Abstract
Background: Sentinel node biopsy (SNB) is the procedure of choice for early breast cancer (BC) patients with clinically negative nodes. Veronesi et al proved that SNB provides an accurate representation of the patient’s true axillary status. The NSABP B-32 trial further confirmed that when the sentinel node is negative, SNB alone is an appropriate, effective and safe treatment for early BC. However, in the Philippine setting, due to concerns over oncologic safety and axillary recurrence, reluctance in the adoption of SNB occurred.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
